In contrast, systemic treatment with Ac2-26 reduced the IL-1β, IL-6 and GRO/KC levels, confirming its anti-inflammatory role as having been demonstrated in other experimental models of neuroinflammation and uveitis and ocular allergies [17, 18, 25, 26, 52]. The gene discussed is IL6; the disease is uveitis.